Introduction
Soft tissue sarcomas (STS) are a group of potentially devastating malignancies of putative mesenchymal origin with over 9500 new cases anticipated in the US during 2006. 1 Overall survival is approximately 50% at 5 years depending upon tumor size, grade, location, the presence of regional or distant disease, as well as responsiveness to surgical, radiation and/or chemotherapeutic approaches. Approximately 60% of STS occur in the extremities, and evidence that amputation does not improve overall survival rates 2 resulted in limb sparing becoming a major therapeutic goal. Developments such as limb salvage surgery with microvascular reconstruction and conformal radiotherapy have improved primary STS control; however, in spite of advances in multimodality limb sparing therapy, local recurrence rates approach 20% at 5 years. 3 Late recurrence is also a feature of treated primary extremity STS and in those patients who survive for 5 years, 21% will die of disease during survival years 6-10, and 9% of those who are disease free at 10 years will succumb to STS during survival year 11 or later. 4 Furthermore, up to 10% of extremity STS are not amenable to limb salvage, 5 and many of the patients in whom limb salvage is achieved sustain significant extremity dysfunction. Consequently, there is a crucial need for novel therapeutics to be incorporated in the multimodality management of extremity STS to improve local control, decrease local recurrence, and hopefully reduce the occurrence of disseminated disease, thereby improving survival.
One possible method to improve extremity STS local control is via isolated limb perfusion (ILP). ILP is an established surgical approach that is currently used to deliver high-dose cytotoxic agents to a tumor-bearing limb for the treatment of unresectable extremity sarcoma or other tumor types such as melanoma with in-transit metastases. 6, 7 In the ILP procedure, biologic and chemotherapeutic agents such as TNF and melphalan 5 are re-circulated through the tumor-supporting limb vasculature in isolation from the systemic circulation, thus minimizing systemic exposure and side effects from the therapy by tightly controlling regional delivery. However, as the use of the described therapeutic agents obviates the need for immediate amputation in the vast majority of patients, it also results in major toxic effects in the exposed limb, leading to significant functional sequela, and can also lead to eventual amputation owing to toxicity. Furthermore, the use of high-dose chemotherapy and even tumor necrosis factor (TNF) does not eliminate the later development of local recurrence. It is possible that use of ILP to deliver novel tumor-targeted therapies could result in higher response rates combined with less toxicity to the surrounding normal tissues. To investigate this hypothesis, we have developed previously a preclinical nude rat model that simulates clinical ILP. 8 New developments in molecular biology are facilitating the emergence of rationally designed, targeted cancer gene therapies. Several initial attempts at gene therapy for STS in preclinical and clinical contexts have been reported. 9 The major obstacles limiting the successful use of gene therapy for STS are similar to those in other malignancies including inefficient delivery methods and the inability to selectively and sustainably target only tumor cells. ILP, which can effectively control leakage from the perfusion circuit to the systemic circulation, has been proposed as a potential gene delivery system for extremity STS. 8, 9 The rat ILP model in particular lends itself to the in vivo assessment of gene therapy-based treatment strategies. Indeed, ILP delivery has been shown to be the most effective method of delivery of therapeutic adenoviruses in at least one important study, 10, 11 and adenoviruses bearing LacZ, 8 luciferase, 12 anti-p21 ras scFV 13 and interleukin 3b 10 have been successfully introduced by ILP delivery into rat limbs harboring rodent or human tumors.
The current studies were designed to assess the feasibility of: (1) delivering therapeutic adenovirus bearing p53 by ILP and (2) targeting the vector specifically to STS cells (transductional targeting) and restricting transgene expression to the STS cells (transcriptional targeting). We sought to address the first issue for several reasons. First, p53 is the most frequently detected mutation in STS, and reconstitution of its wildtype function confers a number of well-documented anticancer outcomes such as growth arrest, 14, 15 resensitization to chemotherapy, 16 suppression of invasion and attenuation of angiogenesis. 17 Second, we have previously shown that intra-tumoral injection (ITI) of adenoviral delivered wild-type p53 significantly inhibited STS growth in SCID mice. 15 Third, adenovirus delivery of p53 is an accepted novel therapy currently in clinical trials for other cancers such as non-small-cell lung cancer, 18, 19 liver tumors, 20 and glioma; 21 however, to the best of our knowledge this has not been attempted in STS patients. The second aim of this study undertaken was to improve the efficiency of gene delivery, STS targeting and tumor viral transduction.
In these feasibility studies, we report for the first time that the therapeutic replication deficient adenovirus AdFLAGp53 can be delivered by ILP to human SKLMS-1 leiomyosarcoma in vivo. This was accomplished in a modified nude rat-human sarcoma xenograft model, with upregulation of p53-responsive genes within 72 h of delivery. Furthermore, we report our extended feasibility studies using fiber-modified, selectively replication proficient oncolytic adenoviruses which demonstrate that these next-generation therapeutic adenoviruses have improved uptake and expression in STS cell lines and cell strains in vitro, with suppression of cell growth and replication in STS cell lines. We additionally show that these modified viruses can be successfully delivered in vivo by ILP, with tissue selectivity and robust intra-tumoral replication.
Results

In vitro confirmation of AdFLAGp53 function in SKLMS-1 cells
The tumor suppressor gene p53 is mutated in 30-60% of all human STS and restoration of wild-type p53 function in tumor cells leads to suppression of the malignant phenotype principally through transcriptional regulation of downstream effector molecules. Using a replicationdeficient, wild-type fiber adenovirus with cytomegalovirus (CMV) promoter-driven expression of FLAG tagged wild-type p53 (AdFLAGp53) we generated previously, 15 we infected SKLMS-1 cells at 1:5000 virus particle (VP) for 48 h in vitro to confirm viral function and transgene efficacy by Western blot analysis (Figure 1a ). Wild-type p53 transgene expression was detected and associated with upregulation of 14-3-3s and p21 CIP1/WAF1 proteins in our mutant p53 STS cell line. Two bands were detected for p53 as the FLAG tag blotted for is fused to the N-terminal of both full-length p53 and its variantly spliced isoform.
Optimization of the ILP circuit for adenoviral delivery
Previously, we have shown that the ILP surgical model has utility as a method of delivering adenoviruses to extremity sarcoma. 8 Recently, it has been shown that circulating blood factors can bind therapeutic adenoviruses and facilitate hepatic clearance of circulating adenoviruses. 22 Although our perfusion model incorporates both an initial limb blood pool 'wash out' cycle and has a quantified leakage rate of less than 10% perfusate to the systemic circulation, 8 we further refined our delivery mechanism to minimize loss of therapeutic virus to residual blood components in the limb and in the circulating perfusate. This was accomplished by modifying our standard perfusion circuit to draw adenoviruses suspended in sterile saline directly into the afferent limb of the circuit rather than drawing them from the saline reservoir receiving washout from the therapeutic perfusion ( Figure 1b ). This modification of the delivery system ensured that all therapeutic viruses were delivered to the tumor bearing limb vasculature at least once before recirculation perfusion.
To confirm viability of viruses delivered by ILP, supernatants of reservoir perfusate fluid were incubated with SKLMS-1 in vitro. AdLacZ perfusate-treated cells were fixed, assayed and blue-colored product generation was confirmed the following day. AdFLAGp53 perfusate-treated cells were harvested for Western blot analysis and FLAGp53 and p21 expression were also confirmed (data not shown), thereby ensuring control and therapeutic virus viability.
ILP delivery of AdFLAGp53 and AdLacZ to SKLMS-1 xenografts
To investigate the feasibility of delivering AdFLAGp53 using the modified ILP system, we implanted SKLMS-1 cells into the bilateral hind limbs of male nude rats and randomly allocated the animals to receive ITI with control AdLacZ or AdFLAGp53, or ILP with control AdLacZ or AdFLAGp53; randomization occurred when xenografts reached 7 mm in size (doses indicated in Materials and methods). Tumor tissue was removed 72 h after ITI or ILP and subjected to repeated reverse transcription-polymerase chain reaction (RT-PCR) to confirm transgene expression. Total mRNA was extracted from tumor tissue specimens on a tumor-bytumor basis and reverse transcribed under stringent conditions to assure no viral DNA carry over into the generated cDNA pools unique for each tumor. CIP1/WAF1 expression, as a marker for p53 wild-type activity, except for (ii) where primary antibody was omitted to serve as a control for possible background, artifactual and cross-reactive staining related to the IHC procedure. T, tumor margin; M, muscle. Representative sections. All sections were stained and photographed under identical parameters. All images were captured at original magnification of Â 200.
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Semi-nested PCR was used to identify exogenously delivered wild-type p53 when present at low levels owing to low transduction, but additionally minimized falsepositive results from aberrant or mispriming of the excess mutant p53 cDNA that was present in the samples.
Having established the presence and expression of the FLAGp53 viral transgene delivered by ILP, we next sought to confirm in vivo functional activity of the exogenous wild-type p53 in the tumor xenografts. Tumors treated with AdFLAGp53 by ITI and ILP, as well as unperfused and AdLacZ perfused tumors, were paraffin sectioned and immunohistochemicals (IHC) was performed for the wild-type p53 response molecule p21
Cip1/WAF1 Figure 2c shows representative IHC photomicrographs of stained sections demonstrating p21 detection only in those tumors treated with AdFLAGp53. Tumors treated by ITI tended to show focal staining for p21 within the core of the tumor when detected. In contrast, p21 upregulation, when detected in ILP-treated tumors, tended to occur more diffusely and both at the core and at the margins of the tumor ( Figure 2c , panel vi). Taken together, these data confirm the successful ILP delivery of functional AdFLAGp53 to SKLMS-1 STS xenografts in the nude rat model.
Uptake and expression of fiber-modified and replication-selective adenoviruses in STS cell lines and cell strains
Next, we wanted to evaluate whether targeting a replication capable adenoviral vector specifically to STS cells (transductional targeting) and restricting transgene expression to the tumor (transcriptional targeting) could result in enhanced rates of STS viral transduction in vivo. We decided to investigate fiber-modified adenoviruses as a means to increase virus adsorption and uptake, as well as mechanisms of selective viral replication in tumor cells that locally amplify therapeutic viruses in treated STS. Fiber modified adenoviruses have been reported to enhance uptake in difficult to infect leukemic cells, 23 and were used to screen a panel of human and rat STS cell lines for enhanced uptake and expression of the b-galactosidase reporter gene. We found that both RGDand K21-peptide modifications of the adenovirus fiber knob increased viral uptake in all our STS lines by at least one log-order over wild-type fiber virus allowing visualization of the improved gene delivery on even gross inspection (Supplementary Figure 1) .
To test intra-tumoral viral replication in vitro, our panel of STS cell lines and immortalized human fibroblast cell line Hs27 (as a positive control) were incubated with the recently characterized oncolytic adenovirus Ad.hTC.GFP/E1a. 24 In this virus, the E1a-driven replicative life cycle and GFP reporter gene expression is initiated by activity of the hTC promoter. This promoter contains a fragment of the human telomerase promoter and is consequently active in cells with active telomerase activity, such as tumor cells. Western blot analysis of infected-cell lysates showed expression of GFP and E1a in all STS cells tested at standard (1:5000 VP) or reduced (1:1000 VP) infection doses ( Figure 3a ). These data indicated that the Ad.hTC.GFP/E1a virus might be a therapeutic candidate meriting further investigation in STS virotherapy. As we found that RGD-fiber-modified viruses showed enhanced uptake into STS cells, we incubated our STS cell line panel with RGD-fiber-modified Ad.hTC.GFP/ E1a and wild-type fiber viruses Ad.hTC.GFP/E1a and Ad.CMV.GFP at reduced infection doses (1:1000 VP) for 48 h. As shown in Figure 3b and c, GFP-transgene expression confirmed uptake and expression of each virus in the STS cell lines SKLMS-1 and A204 (for additional vector comparisons see Supplementary Figure  2a) . In those viruses with wild-type fibers GFP expression was lower in cells exposed to the hTC promoter compared to the full CMV promoter. However, RGDfiber-modified viruses carrying hTC-driven transgenes appeared to not only infect more cells but also demonstrated higher transgene expression in infected cells, perhaps as a consequence of enhanced viral uptake.
Long-term tissue culture and in vitro passage of STS cell lines may select for clonal populations with active telomerase, with the result that our findings of AdhTC.GFP.E1a activity in our panel of cell lines may not reflect activity in vivo within tumors. To address this concern, we incubated RGD-fiber-modified Ad.hTC. GFP/E1a and wild-type fiber viruses Ad.hTC.GFP/E1a and Ad.CMV.GFP at reduced infection doses with three cell strains of low passage number that had been recently isolated from patient STS samples. Interestingly, as shown in Figure 3 , hTC activity was robust in all cell strains tested with generation of the late viral protein hexon providing evidence of viral replication (Figure 3d ). We concluded that enhanced uptake and expression from Ad.hTC.GFP/E1a.RGD is not a phenomenon restricted to STS cell lines in vitro but may also be applicable to sarcomas of greater clinical relevance. Infection, replication and local release of functional virus are only of theoretical clinical use unless oncosuppressive effects can be demonstrated. We performed 3 0 -(l-(phenylaminocarbonyl)-3,4-tetrazolium)-bis-acid(4-methoxy-6-nitro)benzen sulfonic acid hydrat (XTT) viability studies on Hs27, SKLMS-1 and SW872 cell lines infected with low doses of Ad.hTC.GFP/E1a.RGD, control Ad.CMV.GFP.RGD and mock treatment to assess the onco-suppressive properties of our candidate therapeutic virus. After 1 week of incubation (Figure 4b ), the viability of the Ad.hTC.GFP/E1a.RGD-infected cells was significantly suppressed at both doses tested compared to controls (for additional vector comparisons see Supplementary Figure 2c ). Taken together, these in vitro data indicate that the candidate adenoviral therapeutic Ad.hTC.GFP/E1a.RGD had enhanced uptake into STS cells compared to wild-type fiber viruses, demonstrated synthesis of hTC-driven transgenes initiating viral replication and release of infectious virions, and suppressed tumor cell growth.
Fiber-modified, selectively replication proficient adenoviruses delivered to STS by ILP demonstrate tumor infection, viral replication and tumor cell death
Using our optimized ILP model, we sought to assess the feasibility of regionally delivering Ad.hTC.GFP/ E1a.RGD to established limb sarcoma. Nude rats bearing xenografted SKLMS-1 human leiomyosarcoma were randomly allocated to receive ILP with either Ad.CMV.GFP.RGD or Ad.hTC.GFP/E1a.RGD once tumors reached 7 mm diameter. Post-perfusion reservoir effluent fluid was incubated with cells in culture to confirm sustained viability, and tumor cell inhibitory Figure 3) . Pre-, 7 days and 14 days post procedure liver function tests (aspartate aminotransferase, alanine aminotransferase, alkaline phosphate, lactate dehydrogenase) all remained within normal rat age-specific limits (data not shown), suggesting the safety of the procedure and the construct.
To grossly assess GFP transgene expression and viral replication, animals were euthanized on day 21 postprocedure and tumors immediately bivalved for brightfield and fluorescence photography before fixation. All tumors perfused with replication proficient virus Ad.hTC.GFP/E1a.RGD readily demonstrated robust GFP fluorescence only within the perfused-tumor tissue ( Figure 5 ). No GFP fluorescence was identified in the non-replicating control-virus perfused tumors.
The strong GFP signal emanating from the Ad.hTC.GFP/E1a.RGD perfused tumors indicated that local viral replication could be occurring within the tumor. To confirm intra-tumoral viral replication, IHC was performed for early (E1a) and late (hexon) viral protein expression on serial sections from tumors perfused with Ad.hTC.GFP/E1a.RGD and Ad.CMV.GFP.RGD viruses. Swathes of concentric regions of E1a and hexon protein expression were identified throughout Ad.hTC.GFP/E1a.RGD, but not Ad.CMV.GFP.RGD, perfused tumors ( Figure 6 ). Additionally, replicating viral proteins were found in regions in close microscopic proximity to pockets of karyorrhectic nuclei in Ad.hTC.GFP/E1a.RGD perfused tumors. Apoptag staining of serial sections revealed foci of terminal deoxynucleotidyl transferase-mediated digoxigenin nick end-labeling (TUNEL) positivity correlating to regions central to hexon and E1a staining ( Figure 6 ). Taken together, these data demonstrate that Ad.hTC.GFP/E1a.RGD delivered by ILP persists in tumor xenografts in a manner consistent with intratumoral viral replication and tumor cell killing.
Discussion
In this study, we examined the feasibility of regionally delivering potentially therapeutic adenovirus-based gene therapy strategies against human STS by ILP, simulating the clinical technique in an STS-xenograft nude rat hind limb model. On the basis of our results, we conclude that the reintroduction of functional wild-type p53 into STS cells harboring a p53 mutation is possible when delivered via isolated limb perfusion. Additionally, our findings suggest that the fiber-modified, selectively replication proficient oncolytic virus Ad.hTC.GFP/ E1a.RGD is particularly efficacious and should be further investigated in the context of STS therapy.
In our previously published work to develop an ILP model that mimics the clinical scenario, 8 we suggested that this model could be useful in testing preclinical restorative gene therapy. Our data presented above establishes the ILP model in this investigative context as remarkably effective for delivery and expression of wild-type and fiber-modified viruses in xenografted human sarcoma. ILP delivery of therapeutic viruses theoretically has a number of inherent advantages over systemic or intra-tumoral delivery; these include minimization of systemic exposure to the therapeutic agent so delivered, attainment of higher regional concentrations of the therapeutic agent and treatment of in-transit disease. Furthermore, recent in vitro studies of fibermodified replication-competent adenoviruses against melanoma 25 and osteosarcoma 26 have identified RGDfiber modifications as facilitating uptake in these tumor types as well. As ILP is a clinically applicable method for advanced melanoma confined to the limb, and has also been suggested for other extremity tumors such as osteosarcoma, further studies of ILP delivery of these next generation adenoviruses clearly needs to be undertaken in the hope of expanding our modest armamentarium of agents against these particularly aggressive malignancies. p53 gene mutations are the most frequently described alterations in STS.
14 Such mutations are found more frequently in metastases as compared to primary tumor, and in high-grade versus low-grade sarcomas. p53 alterations have significant negative impact on both overall as well as sarcoma-specific survival. [27] [28] [29] Our own investigations utilizing autologous human primary and metastatic sarcoma have demonstrated that clonal expansion of p53-mutated cells in STS confers a distinct metastatic advantage, 30 and we have previously shown that re-expression of wild-type p53 into STS cells harboring a p53 mutation can induce apoptosis, enhance chemosensitivity, inhibit angiogenesis and prolong survival in vitro and in vivo. [15] [16] [17] Taking these findings into account, it is logical to investigate the role of wild-type p53 as a therapeutic agent in STS, and results from our preclinical sarcoma models are encouraging. For instance, tumor cell transfection with wild-type p53 caused tumor regression in 40% of mice so treated 15 and also restored STS sensitivity to doxorubicin by downregulating the multidrug-resistance protein-1 (MDR1). 16 Furthermore, ITI of FLAGp53 resulted in significant tumor growth inhibition. 15 Using ILP instead of ITI of the viral construct, we now report a more diffuse pattern of transgene expression suggesting a possibly more efficient delivery system. Moreover, ILP delivery confers the additional advantage of treating micrometastatic deposits through out the affected limb, perhaps thereby reducing the risk of local recurrence.
Although not yet clinically explored in STS, restoration of wild-type p53 into tumors containing a p53 mutation is the subject of intense clinical investigation in a wide range of human malignancies. Clinical trials using replication-defective adenovirus vectors (Adp53), administered by intra-tumoral, intravesical, and intravascular routes have demonstrated p53 gene expression in tumors without demonstrable upregulation of p53-dependent genes (e.g. p21, bax), and unfortunately no significant antitumor effects. 31 In contrast, intraperitoneal administration of Adp53 to ovarian cancer patients resulted in transgene expression and upregulation of p53-dependent genes in the majority of patients. In these patients, this gene therapy was safe to administer in combination with systemic chemotherapy, but significant therapeutic benefits were not seen, perhaps owing to dominant mutant p53 which is frequently expressed in ovarian cancers, where formation of inhibitory heterodimers with the wild-type p53 are observed. 32 Direct injection of Adp53 into brain tumors before resection has resulted in similar evidence of biological activity observable in only a limited region around the injection site. These studies indicate the limitations of both the route of transgene administration (which might be overcome in STS by using ILP as the mode of delivery) and also the limitations of using non-replicating adenovirus vectors for transgene tumor targeting.
The disappointing level of transgene expression observed in the clinical trials discussed above led to our identifying the following strategic factors as Isolated limb perfusion of sarcoma with adenoviruses J Hannay et al amenable to improving therapeutic-virus efficacy in STS management: (1) increasing the virus fiber-cell receptor specificity to increase viral adsorption to STS cells, (2) engineering an expression cassette promoter to select for, or have higher activity in, a tumor intracellular environment, (3) enable viral replication and local amplification within the tumor tissue to generate more agent immediately available at the site of disease and (4) permit oncolysis that might obviate concerns regarding biological activity and narrow effector profile of 'payload' transgenes within the heterogeneous intracellular environments of tumor cells. Our findings demonstrate that addressing each of these factors with Ad.hTC.GFP/ E1a.RGD greatly enhances sarcoma transduction in vitro and in vivo. These strategies were successfully adopted and robust tumor-selective viral replication was seen in vivo in our model with no overt hepato-toxicity. Although the present study aim was only to assess the feasibility of therapeutic virus delivery, to address in vivo therapeutic efficacy of Ad.hTC.GFP/E1a.RGD, perfused tumors would need to be monitored for longer than 2-3 viral life cycles (21 days), as will be carried out in future studies. Replacement of the GFP gene in Ad.hTC.GFP/E1a.RGD with more therapeutically relevant genes such as with p53, TRAIL or TNFa can be anticipated to possibly enhance the tumoricidal effect of this tumor tropic virus, and these studies are currently underway.
Cancer is a complex, highly adaptable multi-step process and consequently for gene therapy to be effective, will probably require highly efficient gene transfer at the tumor site. For this reason, gene therapy via ILP is not envisioned as a 'stand alone' therapy for extremity tumor management but as a complementary adjunct to standard anticancer approaches such as doxorubicin and melphalan-based chemotherapy and radiotherapy. Future study of p53 replacement might be best focused on the synergy between p53 correction and conventional therapies, as observed in pre-clinical studies. 33, 34 Oncolytic viruses might be expected to lack cross-resistance with standard cytotoxic agents, and coadministration with chemo-radiation does not appear to restrict intra-tumoral viral replication. 35 Ongoing studies will address selection of the optimum replicating-vector in combination with other gene therapy strategies, in addition to exploiting possible synergistic interactions with chemotherapy and radiotherapy.
Materials and methods
Cells and cell culture
Human SKLMS-1 (leiomyosarcoma), SW684 (fibrosarcoma), SW872 (liposarcoma), RD & A204 (both rhabdomyosarcoma) and Hs27 (immortalized normal fibroblast) cells were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in Dulbecco's modified Eagle's medium (DMEM)/F-12 medium (A204 in McCoy5A) with 10% FBS (Life Technologies, Grand Island, NY, USA) in 5% CO 2 and 95% air at 371C. Rat fibrosarcoma (RFS) and cell strains were generated in our lab as described previously 36 and maintained in RPMI and DMEM, respectively, supplemented as above. Cells were passaged by treatment with 0.25% trypsin and 1 mM ethylenediaminetetra acetic acid (EDTA). Cells were infected with viruses in vitro when B50-65% confluent.
Viruses
Recombinant E1a deleted replication-deficient serotype 5 adenoviruses were generated as described previously. 15 Expression cassettes, under the control of the CMV promoter, contained the b-galactosidase reporter gene or p53 wild-type cDNA fused to the FLAG sequence tag and were designated AdLacZ and AdFLAGp53, respectively. RGD-and K21-fiber-modified viruses bearing CMV-driven b-galactosidase expression were a kind gift from Dr Frank Marini, MD Anderson Cancer Center and described previously. 23 Ad.CMV.GFP, Ad.hTC.GFP/ E1a.wt (wild-type fiber) and Ad.hTC.GFP/E1a.RGD (RGD-fiber-modified) viruses were generated and supplied by the WM Keck Center for Cancer Gene TherapyVector Core Laboratory at the MD Anderson Cancer Center. Generation and characterization of the hTC.GFP/ E1a oncolytic adenovirus has been described previously. 24 Virus amplification, determination of VP and plaque-forming assays (PFU) were carried out by the WM Keck Center for Cancer Gene Therapy-Vector Core Laboratory. Viruses were stored at À801C and diluted for use using 10% glycerol in PBS. PFU:VP ratios were within 1:20-1:50 range.
Animals
Eight-week-old male nude rats (nine per study) were purchased from Harlan (Harlan, Indianapolis, IN, USA) and housed in pathogen-free veterinary facilities at MD Anderson Cancer Center. Following 1 week acclimatization, the rats received immunosuppressive total body irradiation of 500 cGy to facilitate bilateral subcutaneous implantation of 1 million proliferating SKLMS-1 cells in 50 ml matrigel per hind limb. For studies of Ad.hTC.GFP/E1a.RGD viruses, 10 6 cells were implanted into the right and 5 Â 10 5 cells implanted into the left hind limbs. Animals were monitored daily for tumor growth. All animal experiments were in accordance with NIH guidelines and approved institutional animal care and use committee protocols.
Viral delivery
AdFLAGp53 feasibility study: once right leg tumors reached 7 mm diameter, viruses were administered by either direct intratumoral injection (AdLacZ at 2 Â or 8 Â 10 11 VP and AdFLAGp53 at 5 Â 10 10 VP in 50 ml saline) or ILP (AdLacZ at 6 Â 10 11 and 4 Â 10 12 VP; AdFLAGp53 at 1 Â (twice), 2 Â , or 6Â 10 11 VP). AdhTC.GFP/E1aRGD study: animals with 7 mm diameter xenografts were randomly allocated to receive ILP with either AdCMV.GFP.RGD (four rats) or Ad.hTC.GFP/ E1a.RGD (five rats) at 10 11 VP. ILP was carried out on anesthetized rats as described previously 8 but modified as described below. Briefly, anesthesia was induced using ketamine HCl (63 mg/ml), xylazine (3.6 mg/ml) and atropine (0.07 mg/ml) cocktail delivered intramuscularly titrated according to rat body weight (0.9 ml mix/kg) and supplemented with the analgesic buprinex (0.1 mg/kg). Maintenance of anesthesia utilized inhalation of isoflurane at 1-2%. With the animal shaved from the waist down, prepped with betadine and loosely taped in a supine manner on a heated table, a 2 cm incision was made in the right inguinal region and deepened down to identify the right femoral artery and vein. These vessels were individually cannulated to allow perfusion of the limb in isolation from the rest of the circulation following tightening of a proximally placed tourniquet under the right inguinal ligament. Perfusion of heparinized saline was carried out for 1 min before therapeutic administration at a rate of 2.2-2.6 ml/min for 5 min in which therapy was drawn directly into the arterial perfusion loop from a syringe and thereafter recirculated. There was no oxygenation of the perfusate and no washout step. Following completion of perfusion, the femoral vessels were ligated, hemostasis assured and a two-layered closure of the wound undertaken with interrupted 5-0 nylon used for skin closure. On the third day post-administration of AdLacZ and AdFLAGp53 adenoviruses, animals were euthanized and underwent rapid necropsy retrieval of tumor and tissue samples. Tumor chip samples were frozen in liquid nitrogen within 4 min of animal euthanasia or fixed in 10% neutral buffered formalin. Animals perfused with RGD-fiber-modified viruses were euthanized at day 21, hind limbs amputated and tumors bivalved in situ for GFP and brightfield photography.
Western blot
Cell monolayers infected in vitro with test adenoviruses were harvested at 48 h post-infection in 1% sodium dodecyl sulfate (SDS) in 50 mM Tris, 10 mM EDTA lysis buffer pH 8.0 supplemented with 1 mM phenylmethylsulphonyl fluoride, 1 mM Na 3 VO 4 and 1 mM NaF. Lysates were clarified by centrifugation before protein quantization of supernatants using Pierce BCA kit (Pierce Biotechnology Inc., Rockford, IL, USA). Equimolar protein aliquots were separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, blocked in 5% milk-Tris-buffered saline (TBS), and probed with appropriate antibodies. Horse radish peroxidase-linked secondary antibodies were detected by enhanced chemiluminescence (Amersham Biosciences Corp., Piscataway, NJ, USA). IRdye680-and IRdye800-conjugated secondary antibodies (Molecular Probes, Carlsbad, CA, USA) were detected using Odyssey Imaging (LI-COR Biosciences, Lincoln, NE, USA).
Antibodies FLAG (M2) and b-actin (Sigma-Aldrich Corp., St Louis, MO, USA); 14-3-3s (N-14), p21 (C-19), GFP (FL), and E1a (13-S-5) (Santa Cruz Biotechnology Inc., Santa-Cruz, CA, USA); hexon (AB1056) (Chemicon International, Temecula, CA, USA); b-galactosidase (Promega, Madison, WI, USA).
Reverse transcription and polymerase chain reaction
Frozen tumor chips of 30 mg weight were subject to homogenization and RNA extraction using RNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA), according to the manufacturer's instructions, and subjected to doubleround purification and on-column DNAse digestion. One microgram of purified RNA was reverse transcribed into cDNA using SuperScript First Strand Synthesis (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. PCR was carried out using 2 ml of purified cDNA and HotStarTaq (Qiagen Inc.,) in 25 ml volumes under the following conditions: 15 min at 951C followed by 40 cycles of 951C for 1 min, 601C for 1 min, 721C for 1 min 30 s, then final extension step at 721C for 7 min before an indefinite 41C soak step. Primers: b-gal forward (5 0 -ttcactggcccgtcgttttacaacgtcgt ga-3 0 ), b-gal reverse (5 0 -atgtgagcgagtaacaacccgtcggattct-3 0 ), FLAG-specific forward (5 0 -atggactacaaggacgacgat gac-3 0 ), p53 wild-type forward (5 0 -tactcccctgccctcaa-3 0 ) and p53 wild-type reverse (5 0 -gttgggcagtgctcgct-3 0 ). PCR products were resolved on a 1.2% agarose gel and photographed under ultraviolet light following ethidium bromide washing of the gel.
Immunohistochemistry
Optimal cutting medium-embedded frozen tissue samples were sectioned to 5-6 mm for X-gal and anti-FLAG staining. Formalin-fixed paraffin-imbedded tissue sections were cut to 5 mm before dewaxing and rehydration through step-wise immersion in xylene and standard ethanol dilutions to water. Sections were microwaved in a 10 mM sodium citrate solution pH 6.0 for antigen retrieval. Endogenous peroxidase activity was quenched with 1% hydrogen peroxide in TBS/calcium solution at room temperature for 30 min before blocking with 5% horse serum in 1% bovine serum albumin (BSA), or DAKO protein block, in phosphate buffered saline (PBS) overnight at 41C. Antibodies, applied in 1% BSA-PBS, were: p21 (C-19) 1:50, E1a (13-S-5) 1:100; hexon (AB1056) 1:100; and detected using DAKOs Envision kit (DakoCytomation, Carpinteria, CA, USA) with diaminobenzidine tetrahydrochloride development before counterstaining with hematoxylin and step-wise dehydration. TUNEL based detection of apoptotic cells was performed with ApopTagPeroxidase In Situ Apoptosis Detection kit (Chemicon International, Temecula, CA, USA) according to manufacturer's protocol and counterstained with 0.5% methyl green. Images were captured using Image Pro Plus software and CoolSNAP-Pro cf (Media Cybernetics Inc., Silver Springs, MD, USA) camera on a Leica DMLA microscope.
b-Galactosidase assay STS cell lines were seeded at 10 5 (SKLMS-1, SW872) or 2 Â 10 5 (SW684, RD, A204, RFS) cells per well in 24-well plates and incubated overnight at 371C before addition of wild-type, RGD-, or K21-fiber-modified viruses at mock, 1:50, 500, 5000 cell to VP ratios for subsequent 48 h. Monolayers were then fixed in 0.05% gluteraldehyde/ PBS solution (0.5 ml/well) at room temperature for 15 min, rinsed with 1 ml PBS for 15 min and 0.5 ml of X-gal working solution (10 mM potassium ferrocyanate, 10 mM potassium ferricyanate, 1 mM magnesium chloride and 1 mg/ml X-gal in PBS) added for 1 h at 371C in the dark. Images were captured from the plates using a HP scanjet 4470c bench-top scanner and Adobe Photoshop software. Experiment was repeated twice.
XTT assay
Equal numbers of Hs27, SKLMS-1 and SW872 cells were plated in 96-well plates and incubated with indicated viruses, or mock-infected, at 100 and 1000 VP:cell ratios for 7 days at 371C. XTT cell viability assay was performed using Cell Proliferation Kit II (Roche Diagnostics Corp., Indianapolis, IN, USA) according to manufacturer's protocol. 
FACS analysis
Parallel plates containing equal numbers of Hs27, SKLMS-1, and SW872 cells were infected, or mock, with Ad.CMV.GFP.RGD and Ad.hTC.GFP/E1a.RGD at VP of 10 and incubated for 4 and 8 days at 371C. Cells were then analyzed in a FACS Calibur and data analyzed with Cell Quest and ModFitLT v3.1 software (Verity Software House, Topsham, ME, USA).
